

Resource Summary Report

Generated by [RRID](#) on Aug 22, 2026

LentiV_Cas9_puro

RRID:Addgene_108100

Type: Plasmid

Proper Citation

RRID:Addgene_108100

Plasmid Information

URL: <http://www.addgene.org/108100>

Proper Citation: RRID:Addgene_108100

Insert Name: Cas9

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:29526696](#)

Vector Backbone Description: Backbone Size:7000; Vector Backbone:LentiV_puro;
Vector Types:Mammalian Expression, Lentiviral, CRISPR; Bacterial Resistance:Ampicillin

Plasmid Name: LentiV_Cas9_puro

Record Creation Time: 20220422T221524+0000

Record Last Update: 20260815T080116+0000

Ratings and Alerts

No rating or validation information has been found for LentiV_Cas9_puro.

No alerts have been found for LentiV_Cas9_puro.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 60 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shi L, et al. (2026) Mapping kinase-dependent tumor immune adaptation with multiplexed single-cell CRISPR screens. *bioRxiv : the preprint server for biology*.

Sreekumar A, et al. (2026) Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy. *Cancer discovery*, 16(4), 781.

Clayfield L, et al. (2026) Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemia. *Cell reports*, 45(2), 116875.

Cao Z, et al. (2026) CRISPR-based functional genomics for dissecting therapeutic dependency in primary acute myeloid leukemia samples. *Molecular cell*, 86(5), 968.

Vargas C, et al. (2025) CD44 Marks Dormant Tumor Cells After HER2 Inhibition in Breast Cancer Cells. *International journal of molecular sciences*, 26(10).

Li C, et al. (2025) Liver-breast communication of adipocyte-oriented exosomes drives primary mammary cancer progression. *Cell metabolism*.

Zheng S, et al. (2025) Phosphorylation of plectin by Akt3 promotes triple-negative breast cancer cell invasive migration. *iScience*, 28(10), 113552.

Johnson CS, et al. (2025) Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer. *Molecular cancer research : MCR*, 23(8), 739.

Todorov TZ, et al. (2025) Phosphoproteomics Reveals L1CAM-Associated Signaling Networks in High-Grade Serous Ovarian Carcinoma: Implications for Radioresistance and Tumorigenesis. *International journal of molecular sciences*, 26(10).

Julian L, et al. (2025) On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions. *bioRxiv : the preprint server for biology*.

Alpsoy A, et al. (2025) Structural basis of DNA-dependent coactivator recruitment by the tuft cell master regulator POU2F3. *Cell reports*, 44(11), 116572.

Zhang P, et al. (2025) Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies. *Cancer discovery*.

Xie M, et al. (2025) Tumor-resident probiotic *Clostridium butyricum* improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. *Cancer cell*.

Tonelli C, et al. (2025) FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development. *Cancer research*, 85(11), 1960.

Xu S, et al. (2025) SWI/SNF complex-mediated ZNF410 cooperative binding maintains chromatin accessibility and enhancer activity. *Cell reports*, 44(4), 115476.

Liao Y, et al. (2024) Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2. *Cell chemical biology*, 31(2), 284.

He T, et al. (2024) Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies. *bioRxiv : the preprint server for biology*.

He T, et al. (2024) Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. *Cancer cell*, 42(8), 1336.

Zhao J, et al. (2024) Oncogenic transcription factors instruct promoter-enhancer hubs in individual triple negative breast cancer cells. *Science advances*, 10(32), ead14043.

Alpsoy A, et al. (2024) I?B? is a dual-use coactivator of NF-?B and POU transcription factors. *Molecular cell*, 84(6), 1149.